Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Mogamulizumab Hits Primary Endpoint in PIII for CTCL: Kyowa Kirin
April 10, 2017
- Kyowa Kirin’s KRN23 Delivers Positive PII Data for Pediatric X-Linked Hypophosphatemia
April 10, 2017
- Takeda-PRA Joint Venture in Japan to Be Formed on June 1
April 10, 2017
- Trerief Delivers Positive Results in Lewy Body Dementia: Sumitomo Dainippon
April 7, 2017
- Boehringer Japan to Spur Joint Drug Discovery Research, Eyes 1st Clinical Trial in 2020
April 7, 2017
- Takeda Earns Global Rights to Finch’s Microbiome IBD Therapy
April 7, 2017
- Takeda’s Massive Dengue Trial Enrollment Completed
April 7, 2017
- Heptares Gains Preclinical Milestone in AZ Immuno-Oncology Deal
April 6, 2017
- Eisai Gets Japan, Asian Rights to Safinamide from Meiji
April 6, 2017
- Actelion’s Flolan Generic Outstrips Originator in Pediatric Use with Rare Dosage Nod; Japan Chief Says Company Fulfilling Maker’s Responsibility
April 6, 2017
- Mochida Aims for Sales of 107 Billion Yen in FY2017 under New 3 Year Biz Plan
April 5, 2017
- Daiichi Sankyo Sells US Packaging Plant
April 5, 2017
- Bayer Yakuhin Running Pilot AI Program for Sales Rep Support
April 5, 2017
- MSD Japan President Pins High Hopes on Keytruda Growth in 2017 after 7.8% Sales Dip
April 5, 2017
- AstraZeneca Transfers 5 Anesthetic Brands to Aspen in Japan under Global Deal
April 4, 2017
- Astellas Acquires Belgium Drug Firm Ogeda
April 4, 2017
- Takeda Consumer Healthcare Spin-Off Now Up and Running
April 4, 2017
- Pfizer Introduces Further Voluntary Recall of EpiPen 0.3 mg in Japan
April 4, 2017
- Alcon Pharma Kicks Off Operations
April 3, 2017
- Pfizer Joins Japan Biosimilar Association
April 3, 2017
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…